Efficacy and Safety of SGLT2 Inhibitors in Patients With Genetic Lipodystrophy: A Real‐Life Experience From a National Reference Network
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.71126 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Léna Robert und 12 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Department, Assistance Publique Des Hopitaux de Paris, AP-HP, Saint-Antoine University Hospital, National Reference Centre for Rare Dis…. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Lipodystrophy, Congenital Generalized, Lipodystrophy, Familial Partial. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: French Ministry of Health, Assistance Publique-Hôpitaux de Paris, Sorbonne University, Sorbonne Université.
Abstract (Originalsprache)
Aim
Lipodystrophy syndromes are rare diseases with metabolic and cardiovascular consequences . This study explores the metabolic and renal effects of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in patients with genetic lipodystrophy. Patients and Methods Patients with familial partial lipodystrophy ( n = 57) or congenital generalised lipodystrophy ( n = 2) (86% women) were initiated with SGLT2i in the French reference network PRISIS. We retrospectively collected clinical and biological data before initiation, after 6–18 months (short‐term, mean ± SD 12.5 ± 6.4 months) and at the latest follow‐up on SGLT2i (long‐term, 29.0 ± 10.7 months).
Results
Body mass index decreased from 25 [22.9–28] (median [IQR]) to 24.4 [22.1–26.5] then 23.9 [22.1–26.4] kg/m 2 ( p < 0.001) and HbA1c from 7.8 [7.1–8.8] to 7.3 [6.7–7.7] and 7.3% [6.9–8] ( p < 0.01 and p = 0.05, respectively). Systolic blood pressure (130 [120–143.25] to 126 [120–137] mmHg), ALT (33 [23.5–44] to 30 [26–40] IU/L), GGT (44 [28.5–62.5] to 37 [27.85–45.5] IU/L) and liver stiffness (6.8 [5.9–11.8] to 5.8 [5–6.9] kPa) declined significantly at short‐term ( p < 0.05, 0.02, 0.02 and < 0.01, respectively). The dual‐energy X‐ray absorptiometry‐based fat mass percentage (23.6 [18–29.3] to 20.8 [17.8–25.3], p = 0.07) and truncal‐to‐lower limb fat ratio (1.36 [1.18–1.50] to 1.17 [0.98–1.41], p = 0.08) tended to decrease at short‐term. Urinary albumin‐to‐creatinine ratio, when elevated at baseline (> 3 mg/mmol, n = 18 patients), decreased from 10.8 [6.3–24.9] to 8.0 mg/mmol [2.8–14.4] ( p = 0.02). Treatment discontinuation (7%) was mainly due to vaginal mycoses. No serious adverse events were reported.
Conclusion
In a real‐life setting, SGLT2i therapy is associated with improvement in HbA1c, body weight, blood pressure, hepatic parameters and albuminuria in patients with genetic lipodystrophy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocrinology Department, Assistance Publique Des Hopitaux de Paris, AP-HP, Saint-Antoine University Hospital, National Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Endo-ERN…
- Sorbonne University, Inserm UMR_S 938, Saint-Antoine Research Centre, Cardiometabolism and Nutrition University Hospital Institute (ICAN), Paris, France.
- Department of Endocrinology, Diabetology, Onco-Endocrinology and Metabolism, Lille University Hospital, Lille, France.
- University of Lille, INSERM U1190, European Genomic Institute for Diabetes, Lille, France.
- Department of Endocrinology, Diabetology and Metabolism, La Réunion University Hospital, Saint Pierre de la Réunion, France.
- Department of Endocrinology, Diabetology and Nutrition CHU La Milétrie, Poitiers, France.
ORCID-Profile: Corinne Vigouroux, Sophie Lamothe
Förderung
- French Ministry of Health, Assistance Publique-Hôpitaux de Paris
- Sorbonne University
- Sorbonne Université
Zitieren
APA
Robert, L., Belalem, I., Vigouroux, C., Dupuis, H., Vantyghem, M. C., Simonson, M., Nobecourt, E., Mosbah, H., Beliard, S., Jellimann, S., Janmaat, S., Vatier, C., & Lamothe, S. (2026). Efficacy and Safety of SGLT2 Inhibitors in Patients With Genetic Lipodystrophy: A Real‐Life Experience From a National Reference Network. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71126
Vancouver
Robert L, Belalem I, Vigouroux C, Dupuis H, Vantyghem MC, Simonson M, et al. Efficacy and Safety of SGLT2 Inhibitors in Patients With Genetic Lipodystrophy: A Real‐Life Experience From a National Reference Network. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71126
BibTeX
@article{Robert2026,
author = {Robert, Léna and Belalem, Ines and Vigouroux, Corinne and Dupuis, Hippolyte and Vantyghem, Marie Christine and Simonson, Mathilde and Nobecourt, Estelle and Mosbah, Héléna and Beliard, Sophie and Jellimann, Stéphanie and Janmaat, Sonja and Vatier, Camille and Lamothe, Sophie},
title = {Efficacy and Safety of SGLT2 Inhibitors in Patients With Genetic Lipodystrophy: A Real‐Life Experience From a National Reference Network},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.71126}
}
EUVIMED